Methamphetamine Use and Schizophrenia: A Population-Based Cohort Study in California
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Clinical investigators in Japan have long suggested that exposure to methamphetamine might cause a persistent schizophrenia-like psychosis. This possibility is discounted in the Western literature. To investigate the relationship between drug use and later schizophrenia, the authors conducted a large-scale cohort study of drug users initially free of persistent psychosis. METHOD: A population-based cohort study was conducted using data from California inpatient hospital discharge records from 1990 through 2000. Patients with methamphetamine-related conditions (N=42,412) and those with other drug use disorders (cannabis, cocaine, alcohol, and opioids) were propensity score-matched to individuals with primary appendicitis who served as a population proxy comparison group; the methamphetamine cohort was also matched to the other drug cohorts. Cox modeling was used to estimate differences between matched groups in the rates of subsequent admission with schizophrenia diagnoses. RESULTS: The methamphetamine cohort had a significantly higher risk of schizophrenia than the appendicitis group (hazard ratio=9.37) and the cocaine, opioid, and alcohol groups (hazard ratios ranging from 1.46 to 2.81), but not significantly different from that of the cannabis group. The risk of schizophrenia was higher in all drug cohorts than in the appendicitis group. CONCLUSIONS: Study limitations include difficulty in confirming schizophrenia diagnoses independent of drug intoxication and the possibility of undetected schizophrenia predating drug exposure. The study's findings suggest that individuals with methamphetamine-related disorders have a higher risk of schizophrenia than those with other drug use disorders, with the exception of cannabis use disorders. The elevated risk in methamphetamine users may be explained by shared etiological mechanisms involved in the development of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The California Hospital Study reported a large association between hospital admission diagnosis of cannabis use disorder and risk of later hospitalisation for schizophrenia (16) compared to a cohort of subjects who were hospitalised for appendicitis (HR 8.16, 95% CI 5.08, 13.12).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [16]
In the citing paper
“Studies that assessed hospitalisation for schizophrenia are unlikely to be substantially affected by this bias (12,16).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [16]
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
McGrath, J., Saha, S., Welham, J., El Saadi, O., MacCauley, C., & Chant, D. (2004) · BMC Medicine · doi:10.1186/1741-7015-2-13 · Cited by 1,072
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002) · BMJ · doi:10.1136/bmj.325.7374.1199 · Cited by 871
Self-citationvan Os, J., Rutten, B. P., & Poulton, R. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn117 · Cited by 713
Stürmer, T., Joshi, M., Glynn, R. J., Avorn, J., Rothman, K. J., & Schneeweiss, S. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.07.004 · Cited by 670
Austin, P. C. (2007) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.07.021 · Cited by 589
Austin, P. C., & Mamdani, M. M. (2006) · Statistics in Medicine · doi:10.1002/sim.2328 · Cited by 560
Shah, B. R., Laupacis, A., Hux, J. E., & Austin, P. C. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.016 · Cited by 493
van Winkel, R., Stefanis, N. C., & Myin-Germeys, I. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn101 · Cited by 489
Appendectomy: A Contemporary Appraisal
Hale, D. A., Molloy, M., Pearl, R. H., Schutt, D. C., & Jaques, D. P. (1997) · Annals of Surgery · doi:10.1097/00000658-199703000-00003 · Cited by 354
Research works printed but not linked: 5
- Angrist B, 1994, Amphetamine and Its Analogs: Pharmacology, Toxicology, and Abuse, 387
- Zach A, 1990, New Way to Edit: Discharge Data Review
- California Office of Statewide Health Planning and Development, 1995, Editing Criteria Handbook
- Sauerland S, 2004, Cochrane Database Syst Rev, 4, CD001546
- Konuma K, 1994, Amphetamine and Its Analogs: Pharmacology, Toxicology, and Abuse, 415
Cited by
Association Between Cannabis and Psychosis: Epidemiologic Evidence
Gage, S. H., Hickman, M., & Zammit, S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.001 · Cited by 379
Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse
Hunt, G. E., Siegfried, N., Morley, K., Sitharthan, T., & Cleary, M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt160 · Cited by 266
Bramness, J. G., Gundersen, Ø. H., Guterstam, J., Rognli, E. B., Konstenius, M., Løberg, E.-M., Medhus, S., Tanum, L., & Franck, J. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-221 · Cited by 243
“The similarities between amphetamines’ and cannabis’ risk of being associated with later psychosis is further supported by a newly published record linkage study [107].”
ResultGage, S. H., Jones, H. J., Burgess, S., Bowden, J., Davey Smith, G., Zammit, S., & Munafò, M. R. (2017) · Psychological Medicine · doi:10.1017/s0033291716003172 · Cited by 211
“Some studies (Callaghan et al. 2012; Rossler et al. 2012), although not all (Gage et al. 2014), conducted since this meta-analysis have also found evidence of an association between cannabis use and later psychotic experiences or schizophrenia.”
BackgroundResultMcKetin, R., Leung, J., Stockings, E., Huo, Y., Foulds, J., Lappin, J. M., Cumming, C., Arunogiri, S., Young, J. T., Sara, G., et al. (2019) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.09.014 · Cited by 191
“no amphetamine use disorder) Callaghan (2012) [40] United States 1990–2000 Patients dependent on amphetamines admitted to Californian hospitals as identified through the California inpatient hospital admissions database CO 91 10,815,900 (36,162) 35 22 Schizophrenia diagnosis”
BackgroundInfluentialWearne, T. A., & Cornish, J. L. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00491 · Cited by 173
Substance use in clinical high risk for psychosis: a review of the literature
Addington, J., Case, N., Saleem, M. M., Auther, A. M., Cornblatt, B. A., & Cadenhead, K. S. (2014) · Early Intervention in Psychiatry · doi:10.1111/eip.12100 · Cited by 122
Psychosocial interventions for people with both severe mental illness and substance misuse
Hunt, G. E., Siegfried, N., Morley, K., Sitharthan, T., & Cleary, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001088.pub3 · Cited by 116
Shin, E., Dang, D., Tran, T.-V., Tran, H., Jeong, J. H., Nah, S.-Y., Jang, C., Yamada, K., Nabeshima, T., & Kim, H. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0897-y · Cited by 110
Psychosocial interventions for people with both severe mental illness and substance misuse
Hunt, G. E., Siegfried, N., Morley, K., Brooke-Sumner, C., & Cleary, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001088.pub4 · Cited by 105
Epigenetics of major psychosis: progress, problems and perspectives
Labrie, V., Pai, S., & Petronis, A. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.04.002 · Cited by 100
“DNMT genes have been reported to be upregulated in the prefrontal cortex of SCZ and BPD patients [46, 47].”
BackgroundInfluentialPsychosis associated with acute recreational drug toxicity: a European case series
Vallersnes, O. M., Dines, A. M., Wood, D. M., Yates, C., Heyerdahl, F., Hovda, K. E., Giraudon, I., & Dargan, P. I. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1002-7 · Cited by 112
“A large cohort study in California found an increased risk of later being diagnosed with schizophrenia in previously non-psychotic hospitalised users of methamphetamine or cannabis [34].”
Psychostimulant use and the brain
Lappin, J., & Sara, G. E. (2019) · Addiction · doi:10.1111/add.14708 · Cited by 108
Nielsen, S. M., Toftdahl, N. G., Nordentoft, M., & Hjorthøj, C. (2017) · Psychological Medicine · doi:10.1017/s0033291717000162 · Cited by 93
“The majority of the papers suggests a causal correlation (Moore et al. 2007; Kuepper et al. 2011; Callaghan et al. 2012; Jordaan & Emsley, 2014).”
BackgroundResultGage, S. H., Hickman, M., Heron, J., Munafò, M. R., Lewis, G., Macleod, J., & Zammit, S. (2014) · Psychological Medicine · doi:10.1017/s0033291714000531 · Cited by 91
“Conclusions from other systematic reviews (Minozzi et al. 2010) and longitudinal studies (Callaghan et al. 2012; Rossler et al. 2012) are broadly consistent, although an earlier review reported inconsistent associations between cannabis use and psychological problems more broadly, and highlighted…”
ResultChlorogenic and Caftaric Acids in Liver Toxicity and Oxidative Stress Induced by Methamphetamine
Koriem, K. M. M., & Soliman, R. E. (2014) · Journal of Toxicology · doi:10.1155/2014/583494 · Cited by 91
O’Connell, K. S., McGregor, N. W., Löchner, C., Emsley, R. A., & Warnich, L. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.02.010 · Cited by 104
Animal models of gene–environment interaction in schizophrenia: A dimensional perspective
Ayhan, Y., McFarland, R., & Pletnikov, M. V. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.002 · Cited by 81
Gage, S. H., Zammit, S., & Hickman, M. (2013) · F1000 Medicine Reports · doi:10.3410/m5-2 · Cited by 78
“A systematic review of the longitudinal studies [7] found consistent empirical evidence that individuals who used cannabis had an increased risk of psychotic outcomes, and studies published since have also reported results consistent with these findings [8,9].”
ResultGiordano, G. N., Ohlsson, H., Sundquist, K., Sundquist, J., & Kendler, K. S. (2015) · Psychological Medicine · doi:10.1017/s0033291714001524 · Cited by 74
“This result is consistent with prior studies showing that stimulant abusers had an increased risk for psychosis (Mitchell & Vierkant, 1991; Chen et al. 2003) and a subsequent diagnosis of schizophrenia (Post, 1975; Callaghan et al. 2012).”
MethodResultWhat can we learn about schizophrenia from studying the human model, drug‐induced psychosis?
Murray, R. M., Paparelli, A., Morrison, P. D., Marconi, A., & Forti, M. D. (2013) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32177 · Cited by 83
“However, recently a cohort of 42,412 patients with methamphetaminerelated conditions were followed-up and compared with individuals with appendicitis; the methamphetamine-using patients were nine times more likely to subsequently receive a diagnosis of schizophrenia [Callaghan et al., 2012].”
ResultEvidence for Shared Genetic Risk Between Methamphetamine-Induced Psychosis and Schizophrenia
Ikeda, M., Okahisa, Y., Aleksić, B., Won, M., Kondo, N., Naruse, N., Aoyama‐Uehara, K., Sora, I., Iyo, M., Hashimoto, R., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.94 · Cited by 67
“…classification of SCZ and the ‘prolonged type’ of METH-induced psychosis, an epidemiological survey suggested that METH abuse patients were at the highest risk of developing SCZ compared with the users of other psychoactive drugs (eg, cocaine, alcohol, opioids, and cannabis; Callaghan et al, 2012).”
Alderson, H. L., Semple, D. M., Blayney, C., Queirazza, F., Chekuri, V., & Lawrie, S. M. (2017) · Psychological Medicine · doi:10.1017/s0033291717001118 · Cited by 69
“There is also evidence that regular use of psychoactive substances is associated with the development of schizophrenia in vulnerable individuals, with the strongest evidence for an association with cannabis use (Semple et al. 2005; Callaghan et al. 2012).”
BackgroundMcKetin, R., Baker, A., Dawe, S., Voce, A., & Lubman, D. I. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.02.028 · Cited by 71
Manning, E. E., & van den Buuse, M. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00092 · Cited by 59
Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users
Chen, C., Lin, S., Chen, Y., Huang, M., Chen, T., Ree, S., & Wang, L. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.12.035 · Cited by 58
Cadet, J. L., Jayanthi, S., McCoy, M. T., Ladenheim, B., Saint-Preux, F., Lehrmann, E., De, S., Becker, K. G., & Brannock, C. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-545 · Cited by 59
“The drug causes behavioral abnormalities that include the development of tolerance and dependence, paranoid states, and psychotic symptoms in human addicts [1,2].”
BackgroundDrugs of abuse and increased risk of psychosis development
Gururajan, A., Manning, E. E., Klug, M., & van den Buuse, M. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412455232 · Cited by 59
“A more recent study reported that the risk of schizophrenia in METH users was equivalent to that of cannabis users compared to a proxy comparison group of appendicitis patients (Callaghan et al., 2012).”
ResultHealey, K. M., Penn, D. L., Perkins, D., Woods, S. W., Keefe, R. S. E., & Addington, J. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx080 · Cited by 46
Auther, A. M., Cadenhead, K. S., Carrión, R. E., Addington, J., Bearden, C. E., Cannon, T. D., McGlashan, T. H., Perkins, D. O., Seidman, L. J., Tsuang, M. T., et al. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12382 · Cited by 47
“Furthermore, a recent cohort study found that methamphetamine use was associated with risk for schizophrenia equivalent to cannabis use (44).”
BackgroundCannabis and Psychosis Through the Lens of DSM-5
Pearson, N., & Berry, J. H. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16214149 · Cited by 78
“The association between cannabis use and a chronic psychotic disorder (either schizophrenia or schizophreniform disorder) in longitudinal studies has been replicated multiple times [58,59].”
BackgroundVolume reductions in frontopolar and left perisylvian cortices in methamphetamine induced psychosis
Aoki, Y. Y., Orikabe, L., Takayanagi, Y., Yahata, N., Mozue, Y., Sudo, Y., Ishii, T., Itokawa, M., Suzuki, M., Kurachi, M., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.04.029 · Cited by 50
Wearne, T. A., Mirzaei, M., Franklin, J. L., Goodchild, A. K., Haynes, P. A., & Cornish, J. L. (2014) · Journal of Proteome Research · doi:10.1021/pr500719f · Cited by 43
Youth Substance Abuse and Co-occurring Disorders
(2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615370221 · Cited by 44
Mätlik, K., Garton, D. R., Montaño-Rodriguez, A., Olfat, S., Eren, F., Casserly, L., Damdimopoulos, A. E., Panhelainen, A. E., Porokuokka, L. L., Kopra, J. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01554-2 · Cited by 44
Meta-Analysis of Structural and Functional Brain Abnormalities in Cocaine Addiction
Dang, J., Tao, Q., Niu, X., Zhang, M., Gao, X., Yang, Z., Yu, M., Wang, W., Han, S., Cheng, J., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.927075 · Cited by 47
The Methamphetamine-Associated Psychosis Spectrum: a Clinically Focused Review
Arunogiri, S., McKetin, R., Verdejo‐García, A., & Lubman, D. I. (2018) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-018-9934-4 · Cited by 40
“In addition, one study estimated that people with methamphetamine-related disorders had a ninefold increase in the risk of developing schizophrenia in comparison to the general population (Callaghan et al. 2012).”
BackgroundEthical issues associated with genetic counseling in the context of adolescent psychiatry
Ryan, J., Virani, A., & Austin, J. (2015) · Applied & Translational Genomics · doi:10.1016/j.atg.2015.06.001 · Cited by 41
“…and methamphetamines (both of which have been associated with increased risk for psychiatric illness; Capsi et al., 2005; Degenhardt and Hall, 2006; Callaghan et al., 2012), and factors that are generally protective to mental health (e.g. healthy balanced diet, regular exercise regime, sleep…”
BackgroundCorrelates of transient versus persistent psychotic symptoms among dependent methamphetamine users
McKetin, R., Gardner, J., Baker, A., Dawe, S., Ali, R. L., Voce, A., Leach, L., & Lubman, D. I. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.02.038 · Cited by 41
“It is unclear whether this persistent psychosis reflects the precipitation of a schizophrenia spectrum disorder in vulnerable individuals (Callaghan et al., 2012; Niemi-Pynttari et al., 2013; Schuckit, 2006) or a chronic form of methamphetamine-induced psychosis (Tomiyama, 1990).”
The neurobiology of relapse in schizophrenia
Remington, G. J., Foussias, G., Agid, O., Fervaha, G., Takeuchi, H., & Hahn, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.009 · Cited by 46
“Risk varies between drugs but, interestingly, includes agents not specifically associated with psychotic symptoms (e.g., alcohol) (Callaghan et al., 2012; Niemi-Pynttari et al., 2013).”
Self-citationBDNF-Deficient Mice Show Reduced Psychosis-Related Behaviors Following Chronic Methamphetamine
Manning, E. E., Halberstadt, A. L., & van den Buuse, M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv116 · Cited by 36
“There is growing evidence that this persistent psychosis is similar to the onset of schizophrenia (Callaghan et al., 2012), which is supported by shared familial and genetic risk between schizophrenia and METH-induced psychosis (Ikeda et al.”
BackgroundHajebi, A., Amini, H., Kashani, L., & Sharifi, V. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12404 · Cited by 34
“cohort study in the United States also showed that use of methamphetamines, similar to cannabis, increased the risk of schizophrenia in the future (Callaghan et al., 2012) and a significant proportion of”
BackgroundPetersen, S. M., Toftdahl, N. G., Nordentoft, M., & Hjorthøj, C. R. (2019) · Addiction · doi:10.1111/add.14746 · Cited by 38
Rognli, E. B., Berge, J., Håkansson, A., & Bramness, J. G. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.032 · Cited by 39
“A longitudinal study of substance-related hospitalizations found amphetamine and cannabis to impose higher risk for schizophrenia than alcohol and opioids, though all substances elevated the risk (Callaghan et al., 2012).”
BackgroundResultLappin, J., Roxburgh, A., Kaye, S. S., Chalmers, J., Sara, G. E., Dobbins, T., Burns, L., & Farrell, M. (2016) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2016.10.018 · Cited by 33
Salo, R. E., Fassbender, C., Iosif, A., Ursu, S., Leamon, M. H., & Carter, C. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.06.030 · Cited by 36
Understanding the Relationship Between Amphetamines and Psychosis
Rognli, E. B., & Bramness, J. G. (2015) · Current Addiction Reports · doi:10.1007/s40429-015-0077-4 · Cited by 35
The Effect of Marijuana Use on the Risk for Schizophrenia [CME]
Evins, A. E., Green, A. I., Kane, J. M., & Murray, R. M. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12012co1c · Cited by 34
Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis
Watts, J. J., Jacobson, M. R., Lalang, N., Boileau, I., Tyndale, R. F., Kiang, M., Ross, R. A., Houle, S., Wilson, A. A., Rusjan, P., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.03.003 · Cited by 35
“Epidemiological studies link cannabis use with increased risk of psychosis (50, 51), and early initiation with a younger age of psychosis onset (52, 53).”
BackgroundSelf-citationYamamuro, K., Makinodan, M., Kimoto, S., Kishimoto, N., Morimoto, T., Toritsuka, M., Matsuoka, K., Takebayashi, Y., Takata, T., Takahashi, M., et al. (2015) · Scientific Reports · doi:10.1038/srep12107 · Cited by 30
Wang, L., Lin, S., Chen, Y., Huang, M., Chen, T., Ree, S., & Chen, C. (2016) · Psychopathology · doi:10.1159/000445065 · Cited by 29
Rognli, E. B., Håkansson, A., Berge, J., & Bramness, J. G. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.07.037 · Cited by 30
“It has also been suggested that the use of amphetamine may e related to the development of a more persistent psychotic yndrome (Callaghan et al., 2012; Zorick et al., 2008).”
BackgroundViolent offences of methamphetamine users and dilemmas of forensic psychiatric assessment
Liu, Y., Hao, B., Shi, Y., Li, X., Wang, X., Chen, Y., & Zhao, H. (2017) · Forensic Sciences Research · doi:10.1080/20961790.2017.1287155 · Cited by 30
“possibility of persistent psychosis than the use of cocaine, opioids, and alcohol [57].”
BackgroundRognli, E. B., Bramness, J. G., Skurtveit, S. O., & Bukten, A. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.12.007 · Cited by 29
Methamphetamine‐related psychosis: an opportunity for assertive intervention and prevention
Lappin, J., Sara, G. E., & Farrell, M. (2016) · Addiction · doi:10.1111/add.13663 · Cited by 24
What is schizophrenia – symptomatology
Striebel, J. M. (2024) · CNS Spectrums · doi:10.1017/s1092852924000622 · Cited by 35
Chesworth, R., Porto, R. R., Yao, S. S., & Karl, T. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120967870 · Cited by 22
Wearne, T. A., Parker, L. M., Franklin, J. L., Goodchild, A. K., & Cornish, J. L. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.038 · Cited by 21
Chen, W.-L., Hsieh, C., Chang, H., Hung, C., & Chan, C.-H. (2015) · Addictive Behaviors · doi:10.1016/j.addbeh.2015.02.013 · Cited by 22
Durbin, A., Rudoler, D., Durbin, J., Laporte, A., & Callaghan, R. C. (2013) · Journal of Immigrant and Minority Health · doi:10.1007/s10903-013-9831-7 · Cited by 22
“In prior work we demonstrated that individuals admitted to hospital with appendicitis-related diagnoses manifest similar trajectories for developing medical outcomes as those found in the general population [37, 38].”
BackgroundResultSelf-citationYang, M., Jia, X., Zhou, H., Ren, P., Deng, H., Kong, Z., Xie, C., Hu, W., Jiang, W., Lai, W., et al. (2021) · Addiction Biology · doi:10.1111/adb.13044 · Cited by 19
Engelgardt, P., Krzyżanowski, M., Borkowska-Sztachańska, M., Wasilewska, A., & Ciucias, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-28603-2 · Cited by 21
Prescription stimulant use is associated with earlier onset of psychosis
Moran, L. V., Masters, G. A., Pingali, S. M., Cohen, B. M., Liebson, E. S., Rajarethinam, R., & Öngür, D. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.09.012 · Cited by 25
Capuzzi, E., Caldiroli, A., Besana, F., Cova, F., Buoli, M., & Clerici, M. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108104 · Cited by 22
Callaghan, R. C., Halliday, M., Gatley, J. M., Sykes, J. R., Taylor, L., Benny, C., & Kish, S. J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.03.030 · Cited by 20
Self-citationJaehne, E. J., Ameti, D., Paiva, T., & van den Buuse, M. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00061 · Cited by 18
“7 mA) or (2) a conditioned stimulus (30 s duration, 7,500 Hz, 70 dB) previously presented prior to the US, but in a new context.”
InfluentialManning, E. E., & van den Buuse, M. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.03.014 · Cited by 19
Sara, G. E., Lappin, J., Dobbins, T., Dunlop, A. J., & Degenhardt, L. J. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.08.009 · Cited by 17
“Young adults admitted to hospital with any methamphetamine-related condition have a 10-fold increased risk of later development of Schizophrenia compared with matched controls admitted with appendicitis (Callaghan et al., 2012).”
BackgroundResultKalayasiri, R., Kraijak, K., Maes, M. H. J., & Mutirangura, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1371-7 · Cited by 16
Adolescent inhalant use and psychosis risk – a prospective longitudinal study
Mustonen, A., Niemelä, S., McGrath, J. J., Murray, G. K., Nordström, T., Mäki, P. H., Miettunen, J., & Scott, J. G. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.05.013 · Cited by 17
Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells
Powell, S. K., O’Shea, C. P., Shannon, S. R., Akbarian, S., & Brennand, K. (2020) · Advances in neurobiology · doi:10.1007/978-3-030-45493-7_6 · Cited by 16
Pettersen, H. (2014) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.1000193 · Cited by 14
“Studies have shown that both cannabis [15,16] and, to a greater extent, amphetamines [17,18] can provoke psychosis.”
Vicente‐Rodríguez, M., Herradón, G., Ferrer‐Alcón, M., Uribarri, M., & Pérez‐García, C. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00130 · Cited by 14
Engel, M., Snikeris, P., Matosin, N., Newell, K. A., Huang, X., & Frank, E. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4230-0 · Cited by 15
“Additionally, stressors that contribute to the development of schizophrenia symptoms include the consumption of illicit substances such as cannabis (Wilkinson et al., 2014), methamphetamine (Callaghan et al., 2012) and phencyclidine (PCP) during adolescence (Swartz et al., 2014).”
BackgroundZito, M. F., Fei, Z., Zhu, Y., Clingan, S. E., Marder, S. R., & Mooney, L. J. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209033 · Cited by 11
Hides, L. M., Chan, G., Dawe, S., McKetin, R., Kavanagh, D. J., Young, R. M., Teesson, M., & Saunders, J. B. (2020) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.263 · Cited by 11
Methamphetamine use and psychotic symptoms: findings from a New Zealand longitudinal birth cohort
Boden, J. M., Foulds, J., Newton‐Howes, G., & McKetin, R. (2021) · Psychological Medicine · doi:10.1017/s0033291721002415 · Cited by 12
Johnstad, P. G. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221095228 · Cited by 13
“…for tobacco use (Addington and Addington, 2007; Alemany et al., 2014; Arseneault et al., 2002; Auther et al., 2015; Brañas et al., 2016, 2017; Callaghan et al., 2012; Corcoran et al., 2008; Di Forti et al., 2014; Dragt et al., 2012; Ferdinand et al., 2005; Foti et al., 2010; Freeman et al.,…”
BackgroundCognitive changes in patients with acute phase psychosis—Effects of illicit drug use
Helle, S., Gjestad, R., Johnsen, E., Kroken, R. A., Jørgensen, H. A., & Løberg, E. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.08.062 · Cited by 14
“This is supported by the fact that having a drug use disorder, in particular cannabis and amphetamines use disorder (Callaghan et al., 2012), or earlier cannabis use, is a risk factor for developing schizophrenia in a dose dependent manner (Andreasson et al.”
BackgroundLee, W., Chang, H., Huang, M., Pan, C., Su, S., Tsai, S., Chen, C.-C., & Kuo, C. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2021.1979990 · Cited by 13
“A large cohort study revealed that methamphetamine use was associated with a 9-fold increased risk of schizophrenia (27), and 39% of methamphetamine users transferred to schizophrenia 1 year after their first hospitalization (28).”
BackgroundThe Association Between Cannabinoids and Psychosis
Tikka, S. K., & D’Souza, D. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-90365-1_14 · Cited by 11
The Pathology of Methamphetamine Use in the Human Brain
Kish, S. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00008-3 · Cited by 11
Self-citationWang, G., Ma, L., Liu, X., Yang, X., Zhang, S., Yang, Y., Xu, Z., & Hao, W. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00656 · Cited by 10
Humphreys, M., Martin, C., Theodoros, T., Andronis, D., & Isoardi, K. (2023) · Emergency Medicine Australasia · doi:10.1111/1742-6723.14287 · Cited by 9
Yang, Z., Klugah‐Brown, B., Ding, G., Zhou, W., & Biswal, B. B. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111159 · Cited by 10
Zhang, Y., Tan, X., Xing, L., Wu, H., & Yang, J. (2021) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.119695 · Cited by 7
The Role of Chinese Herbal Therapy in Methamphetamine Abuse and its Induced Psychiatric Symptoms
Chen, L., Ru, Q., Xiong, Q., Zhou, M., Yue, K., & Wu, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.679905 · Cited by 9
“Related epidemiological and clinical studies have suggested that people abusing METH have a significantly increased risk of schizophrenia (Callaghan et al., 2012) and are more prone to cognitive impairment (Wagner et al.”
BackgroundAhmadkhaniha, H., Ayazi, N., Alavi, K., Najjarzadehgan, M., & Hadi, F. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.2837.1 · Cited by 6
Chou, S., Fish, K. N., Lewis, D. A., & Sweet, R. A. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106262 · Cited by 6
Darvishzadeh, H., Mirzaee, M., Jahani, Y., & Sharifi, H. P. (2019) · PubMed Central · doi:10.22122/ahj.v11i3.231 · Cited by 6
Khalkhali, M., Golshahi, M., Hasandokht, T., Kafie, M., & Zare, R. (2018) · Advanced Biomedical Research · doi:10.4103/abr.abr_14_18 · Cited by 6
“[21] The psychiatric symptoms and clinical course of MIP and schizophrenia are very similar, which make it difficult to distinguish between MIP and schizophrenia.[22,23] Previous studies have not demonstrated a clinically significant distinction between schizophrenia and MIP.”
BackgroundNISHIO, T., Toukairin, Y., Hoshi, T., Arai, T., & Nogami, M. (2025) · Legal Medicine · doi:10.1016/j.legalmed.2025.102650 · Cited by 4
Relações entre o uso de anfetaminas e sintomas psicóticos: uma revisão sistemática
Mesquita, V. H., Rambaldi, R. H., & Proença, R. L. S. (2022) · Revista de Medicina · doi:10.11606/issn.1679-9836.v101i2e-171974 · Cited by 7
Almerge, J. C., Sánchez-Romero, S., & Árias, F. (2023) · Adicciones · doi:10.20882/adicciones.1291 · Cited by 9
“…which are usually transitory in nature (Gage, Hickman & Zammit, 2016) and linked to the development of schizophrenia in vulnerable individuals (Callaghan et al., 2012; Fonseca-Pedrero, Lucas-Molina, Pérez-Albéniz, Inchausti & Ortuño-Sierra, 2020; García Álvarez, Gomar, García-Portilla &…”
BackgroundThe epidemiology of acute methamphetamine toxicity presenting to emergency departments in Hong Kong
Lam, R. P. K., Chan, C. K., Tse, M. L., Lau, E. H. Y., Tsui, M. S. H., & Rainer, T. H. (2023) · Hong Kong Journal of Emergency Medicine · doi:10.1177/10249079231179103 · Cited by 3
“31 Increase in frequency, duration and severity of methamphetamine use are associated with a higher risk of psychotic symptoms, 32,33 which might last for months even after drug abstinence.”
BackgroundModeling Gene–Environment Interaction in Schizophrenia
Jouroukhin, Y., McFarland, R., Ayhan, Y., & Pletnikov, M. V. (2015) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-800981-9.00020-1 · Cited by 3
Chapter 10. Neurobiology of Stimulants
Sofuoglu, M., DeVito, E. E., & Kosten, T. R. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615373970.kb10 · Cited by 4
McKetin, R., Clare, P. J., Castle, D. J., Turner, A., Kelly, P. J., Lubman, D. I., Arunogiri, S., Manning, V., & Berk, M. (2023) · Addiction · doi:10.1111/add.16230 · Cited by 2
“Methamphetamine use also increases the risk of onset schizophrenia [12] and can precipitate and exacerbate psychotic symptoms in people with the disorder [13].”
BackgroundInteractions of Cannabis and Amphetamine-Type Stimulants
Tambaro, S., & Bortolato, M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2294-9_16 · Cited by 7
“In comparison with other psychostimulants, such as cocaine, METH consumption is associated with a markedly high schizophrenia risk [100].”
BackgroundMethamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention
Zhu, L., Ni, T., & Guan, F. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230467 · Cited by 2
Metadata
- Authors
- Callaghan, R. C., Cunningham, J. K., Allebeck, P., Arenovich, T., Sajeev, G., Remington, G., Boileau, I., & Kish, S. J.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- From the Centre for Addiction and Mental Health, Toronto; the Dalla Lana School of Public Health, the Departments of Psychiatry and Pharmacology, Faculty of Medicine, and the Institute of Medical Science, University of Toronto, Toronto; the Department of Family and Community Medicine, University of Arizona, Tucson; and the Department of Public Health Sciences, Karolinska Institutet, Stockholm.
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2012-04
- Volume
- 169
- Issue
- 4
- Pages
- 389-396
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2055556070
- Cited by
- 150
- References
- 30
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 9 · 2023: 9 · 2022: 6 · 2021: 10 · 2020: 6 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 13 · 2015: 35 · 2014: 9 · 2013: 13 · 2012: 6
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R01DA025096, DA071301, DA025096)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- methamphetamine use, schizophrenia, drug use disorders, cannabis use disorder, cocaine dependence, opioid use disorder, alcoholism, psychosis, hospital discharge data, propensity score matching, schizophrenia risk
- MeSH terms
- Adult, California, Female, Humans, Male, Methamphetamine, Middle Aged, Risk Factors, Schizophrenia, Schizophrenic Psychology, Cohort Studies, Diagnosis, Dual (Psychiatry), Amphetamine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.